Retrovirally transduced mouse dendritic cells require CD4+ T cell help to elicit antitumor immunity: Implications for the clinical use of dendritic cells

Journal of Immunology

Volumn 164, Issue 3, 2000, Pages 1243-1250

  Schnell, Stefan ^a   Young, James W ^a   Houghton, Alan N ^a   Sadelain, Michel ^a,b  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DENDRITIC CELL; FEMALE; FLUORESCENCE ACTIVATED CELL SORTER; HELPER CELL; IMMUNOFLUORESCENCE TEST; MAJOR HISTOCOMPATIBILITY COMPLEX; MELANOMA; MIXED LYMPHOCYTE REACTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; RETROVIRUS; TUMOR IMMUNITY;

EID: 0034142253     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.164.3.1243     Document Type: Article

References (42)

1. Banchereau, J., and R. M. Steinman. 1998. Dendritic cells and the control of immunity. Nature 392:245.
2. Pardoll, D. M. 1998. Cancer vaccines. Nat. Med. 4:525.
3. Mayordomo, J. I., T. Zorina, W. J. Storkus, L. Zitvogel, C. Celluzzi, L. D. Falo, C. J. Melief, S. T. Ildstad, W. M. Kast, A. B. Deleo, et al. 1995. Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity. Nat. Med. 1:1297.
4. Celluzzi, C. M., J. I. Mayordomo, W. J. Storkus, M. T. Lotze, and L. D. Falo, Jr. 1996. Peptide-pulsed dendritic cells induce antigen-specific CTL-mediated protective tumor immunity. J. Exp. Med. 183:283.
5. Porgador, A., D. Snyder, and E. Gilboa. 1996. Induction of antitumor immunity using bone marrow-generated dendritic cells. J. Immunol. 156:2918.
6. + helper T cells. J. Exp. Med. 171:1315.
7. Sigal, L. J., H. Reiser, and K. L. Rock. 1998. The role of B7-1 and B7-2 costimulation for the generation of CTL responses in vivo. J. Immunol. 161:2740.
8. Keene, J. A., and J. Forman. 1982. Helper activity is required for the in vivo generation of cytotoxic T lymphocytes. J. Exp. Med. 155:768.
9. + T cell help. J. Exp. Med. 186:65.
10. Kern, D. E., J. P. Klarnet, M. C. Jensen, and P. D. Greenberg. 1986. Requirement tor recognition of class II molecules and processed tumor antigen for optimal generation of syngeneic tumor-specific class I-restricted CTL. J. Immunol. 136: 4303.
11. Zitvogel, L., P. D. Robbins, W. J. Storkus, M. R. Clarke, M. J. Maeurer, R. L. Campbell, C. G. Davis, H. Tahara, R. D. Schreiber, and M. T. Lotze. 1996. Interleukin-12 and B7.1 co-stimulation cooperate in the induction of effective antitumor immunity and therapy of established tumors. Eur. J. Immunol. 26: 1335.
12. Toes, R. E., F. Ossendorp, R. Offringa, and C. J. Melief. 1999. CD4 T cells and their role in antitumor immune responses. J. Exp. Med. 189:753.
13. Rock, K. L., S. Gamble, and L. Rothstein. 1990. Presentation of exogenous antigen with class I major histocompatibility complex molecules. Science 249:918.
14. Shimonkevitz, R., S. Colon, J. W. Kappler, P. Marrack, and H. M. Grey. 1984. Antigen recognition by H-2-restricted T cells. II. A tryptic ovalbumin peptide that substitutes for processed antigen. J. Immunol. 133:2067.
15. Bennett, S. R., F. R. Carbone, F. Karamalis, R. A. Flavell, J. F. Miller, and W. R. Heath. 1998. Help for cytotoxic-T-cell responses is mediated by CD40 signalling. Nature 393:478.
16. + T-helper and a T-killer cell. Nature 393: 474.
17. Schoenberger, S. P., R. E. Toes, E. I. van der Voort, R. Offringa, and C. J. Melief. 1998. T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature 393:480.
18. + T cells in major histocompatibility complex class II-deficient mice. Science 253:1417.
19. Falo, L. D., Jr., M. Kovacsovics-Bankowski, K. Thompson, and K. L. Rock. 1995. Targeting antigen into the phagocytic pathway in vivo induces protective tumour immunity. Nat. Med. 1:649.
20. Riviere, I., K. Brose, and R. C. Mulligan. 1995. Effects of retroviral vector design on expression of human adenosine deaminase in murine bone marrow transplant recipients engrafted with genetically modified cells. Proc. Natl. Acad. Sci. USA 92:6733.
21. Gallardo, H. F., C. Tan, D. Ory, and M. Sadelain. 1997. Recombinant retroviruses pseudotyped with the vesicular stomatitis virus G glycoprotein mediate both stable gene transfer and pseudotransduction in human peripheral blood lymphocytes. Blood 90:952.
22. Markowitz, D., S. Goff, and A. Bank 1988. A safe packaging line for gene transfer separating viral genes on two different plasmids. J. Virol. 62:1120.
23. Riviere, I., and M. Sadelain. 1997. Methods for the construction of retroviral vectors and the generation of high-titer producers. In Methods in Molecular Medicine. Vol. Gene Therapy Protocols. P. Robbins, ed. Humana Press, Totowa pp. 59-78.
24. Inaba, K., M. Inaba, N. Romani, H. Aya, M. Deguchi, S. Ikehara, S. Muramatsu, and R. M. Steinman. 1992. Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor. J. Exp. Med. 176:1693.
25. Heath, A. W., W. W. Wu, and M. C. Howard. 1994. Monoclonal antibodies to murine CD40 define two distinct functional epitopes. Eur. J. Immunol. 24:1828.
26. Lehmann, E. L. 1975. Statistical methods based on ranks. Holden-Day, Boca Raton.
27. Shastri, N., and F. Gonzales. 1993. Endogenous generation and presentation of the ovalbumin peptide/Kb complex to T cells. J. Immunol. 150:2724.
28. Moore, M. W., F. R. Carbone and M. J. Bevan. 1988. Introduction of soluble protein into the class 1 pathway of antigen processing and presentation. Cell 54:777.
29. Sanderson, S., K. Frauwirth, and N. Shastri. 1995. Expression of endogenous peptide-major histocompatibility complex class II complexes derived from invariant chain-antigen fusion proteins. Proc. Natl. Acad. Sci. USA 92:7217.
30. Stuhler, G., A. Zobywalski, F. Grunebach, P. Brossart, V. L. Reichardt, H. Barth, S. Stevanovic, W. Brugger, L. Kanz, and S. F. Schlossman. 1999. Immune regulatory loops determine productive interactions within human T lymphocyte-dendritic cell clusters. Proc. Natl. Acad. Sci. USA 96:1532.
31. van Elsas, A., A. A. Hurwitz, and J. P. Allison. 1999. Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation. J. Exp. Med. 190: 355.
32. Zhang, W., L. He, Z. Yuan, Z. Xie, J. Wang, H. Hamada, and X. Cao. 1999. Enhanced therapeutic efficacy of tumor RNA-pulsed dendritic cells after genetic modification with lymphotactin. Hum. Gene Ther. 10:1151.
33. Mackey, M. P., J. R. Gunn, P. P. Ting, H. Kikutani, G. Dranoff, R. J. Noelle, and R. J. Barth, Jr. 1997. Protective immunity induced by tumor vaccines requires interaction between CD40 and its ligand, CD154. Cancer Res. 57:2569.
34. Mackey, M. F., J. R. Gunn, C. Maliszewsky, H. Kikutani, R. J. Noelle, and R. J. Barth, Jr. 1998. Dendritic cells require maturation via CD40 to generate protective antitumor immunity. J. Immunol. 161:2094.
35. Labeur, M. S., B. Roters, B. Pers, A. Mehling, T. A. Luger, T. Schwarz, and S. Grabbe. 1999. Generation of tumor immunity by bone marrow-derived dendritic cells correlates with dendritic cell maturation stage. J. Immunol. 162:168.
36. French, R. R., H. T. Chan, A. L. Tutt, and M. J. Glennie. 1999. CD40 antibody evokes a cytotoxic T-cell response that eradicates lymphoma and bypasses T-cell help. Nat. Med. 5:548.
37. Diehl, L., A. T. den Boer, S. P. Schoenberger, E. I. van der Voort, T. N. Schumacher, C. J. Melief, R. Offringa, and R. E. Toes. 1999. CD40 activation in vivo overcomes peptide-induced peripheral cytotoxic T-lymphocyte tolerance and augments anti-tumor vaccine efficacy. Nat. Med. 5:774.
38. -/- dendritic cells to provide tumor protection is rescued by CD40 ligation. J. Immunol. 163:77.
39. Bachmann, M. F., B. R. Wong, R. Josien, R. M. Steinman, A. Oxenius, and Y. Choi. 1999. TRANCE, a tumor necrosis factor family member critical for CD40 ligand-independent T helper cell activation. J. Exp. Med. 189: 1025.
40. Koch, F., U. Stanzl, P. Jennewein, K. Janke, C. Heufler, E. Kampgen, N. Romani, and G. Schuler. 1996. High level IL-12 production by murine dendritic cells: upregulation via MHC class II and CD40 molecules and downregulation by IL-4 and IL-10. [Published erratum appears in 1996 J. Exp. Med. 184:1590.] J. Exp. Med. 184:741.
41. Barlow, A. K., X. He, and C. Janeway, Jr. 1998. Exogenously provided peptides of a self-antigen can be processed into forms that are recognized by self-T cells. J. Exp. Med. 187:1403.
42. Szabolcs, P., H. F. Gallardo, D. H. Ciocon, M. Sadelain, and J. W. Young. 1997. Retrovirally transduced human dendritic cells express a normal phenotype and potent T-cell stimulatory capacity. Blood 90:2160.